| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Clinical pharmacokinetics of TNF antagonists: How do they differ?
|
Nestorov, Ivan
|
|
2005
|
|
5S1 |
p. 12-18
7 p.
|
artikel
|
| 2 |
Differentiating the efficacy of the tumor necrosis factor inhibitors
|
Haraoui, Boulos
|
|
2005
|
|
5S1 |
p. 7-11
5 p.
|
artikel
|
| 3 |
Distinct mechanisms of action of tumor necrosis factor antagonists: What are the clinical implications?
|
Rigby, William F.C.
|
|
2005
|
|
5S1 |
p. 1-2
2 p.
|
artikel
|
| 4 |
Diverse effects of infliximab and etanercept on T lymphocytes
|
Sieper, Joachim
|
|
2005
|
|
5S1 |
p. 23-27
5 p.
|
artikel
|
| 5 |
Epidemiology of lymphoma development in patients with rheumatoid arthritis
|
Ekbom, Anders
|
|
2005
|
|
5S1 |
p. 28-30
3 p.
|
artikel
|
| 6 |
Sponsorship page
|
|
|
2005
|
|
5S1 |
p. A2-
1 p.
|
artikel
|
| 7 |
Table of contents
|
|
|
2005
|
|
5S1 |
p. A1-
1 p.
|
artikel
|
| 8 |
TNF pathophysiology in murine models of chronic inflammation and autoimmunity
|
Kollias, George
|
|
2005
|
|
5S1 |
p. 3-6
4 p.
|
artikel
|
| 9 |
Tumor necrosis factor and granuloma biology: Explaining the differential infection risk of etanercept and infliximab
|
Wallis, Robert S.
|
|
2005
|
|
5S1 |
p. 34-38
5 p.
|
artikel
|
| 10 |
Tumor necrosis factor inhibitors: Clinical implications of their different immunogenicity profiles
|
Anderson, Paul J.
|
|
2005
|
|
5S1 |
p. 19-22
4 p.
|
artikel
|
| 11 |
What are the links between Epstein-Barr virus, lymphoma, and tumor necrosis factor antagonism in rheumatoid arthritis?
|
Balandraud, Nathalie
|
|
2005
|
|
5S1 |
p. 31-33
3 p.
|
artikel
|
Tijdschrift beschrijving